Skip to main content

Advertisement

SpringerLink
Log in

Treatment of hypertension in diabetes mellitus

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

In this article we emphasize the need for prompt intervention in diabetic patients with high blood pressure in order to protect the heart, brain, kidney, and the vascular tree against arteriosclerotic damage, which is the main cause of mortality in type 1, and particularly type 2 diabetes mellitus. Recent placebo-controlled, randomized trials indicate that compared with the nondiabetic population, a lower blood pressure threshold for intervention and a lower target blood pressure are adequate in terms of target organ protection. Although all major classes of antihypertensive drugs have demonstrated a potential benefit in treating diabetic hypertensive patients, blocking the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors is especially useful in patients at high risk for myocardial infarction and/or renal damage. The new class of antihypertensive agents that block the angiotensin II receptor have renal effects very close to those observed with ACE inhibitors. The potential role of this new class in the treatment of hypertension in diabetes will depend on the results of ongoing trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Epstein M, Sowers J: Diabetes mellitus and hypertension. Hypertension 1992, 19:403–418.

    PubMed  CAS  Google Scholar 

  2. The National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994, 23:145–158.

    Google Scholar 

  3. Mogensen CE: Management of the diabetic patient with elevated blood pressure and renal disease. Early screening and treatment programs: albuminuria and blood pressure. In Hypertension, Pathophysiology, Diagnosis, and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2336–2365.

    Google Scholar 

  4. Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 1995, 26:869–879.

    PubMed  CAS  Google Scholar 

  5. Standley PR, Ali S, Bapna C, Sowers JR: Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension. Am J Hypertens 1993, 6:938–943.

    PubMed  CAS  Google Scholar 

  6. Carmassi F, Morale M, Puccetti R, et al.: Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992, 67:643–654.

    Article  PubMed  CAS  Google Scholar 

  7. Hseuh WA, Anderson PW: Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992, 20:253–263.

    Google Scholar 

  8. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  CAS  Google Scholar 

  9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  10. Chatuverdi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351:28–31.

    Article  Google Scholar 

  11. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413–2446.

    Article  Google Scholar 

  12. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999, 17:151–183.

    Google Scholar 

  13. Ramsay LE, Williams B, Johnston GD, et al.: Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999, 13:569–592.

    Article  PubMed  CAS  Google Scholar 

  14. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Efects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259. Treatment with the ACE inhibitor ramipril reduces the risk of myocardial infarction, stroke, and cardiovascular death in diabetic patients with previous cardiovascular disease or associated cardiovascular risk factors.

    Article  Google Scholar 

  15. Ruilope LM, Garcïa-Robles R: How far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens 1997, 15(suppl 2):S63-S65.

    CAS  Google Scholar 

  16. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group: Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755–1762. Intensive blood pressure lowering with antihypertensive treatement based on the calcium channel blocker felodipine reduces major cardiovascular events and cardiovascular mortality in diabetic hypertensive patients.

    Article  PubMed  CAS  Google Scholar 

  17. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–712. Tight blood pressure control in hypertensive type 2 diabetics protects against diabetes-related macrovascular and microvascular complications.

    Google Scholar 

  18. Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886–1892.

    Article  PubMed  CAS  Google Scholar 

  19. Hansson L, Lindholm LH, Ekbom T, et al.: for the STOPHypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999, 354:1751–1756. Conventional (diuretics and/or b-blockers) or new drugs (calcium antagonists or ACE inhibitors) are equally effective in preventing cardiovascular disease in elderly patients with hypertension.

    Article  PubMed  CAS  Google Scholar 

  20. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713–720. Captopril and atenolol are equally effective in reducing diabetesrelated complications in type 2 diabetic hypertensive patients with tight blood pressure control (£ 150/85).

    Google Scholar 

  21. Birkenhäger WH, Staessen JA: Treatment of diabetic patients with hypertension. Curr Hypertens Rep 1999, 1:225–231.

    Article  PubMed  Google Scholar 

  22. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645–652.

    Article  PubMed  CAS  Google Scholar 

  23. Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597–603.

    Article  PubMed  CAS  Google Scholar 

  24. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. for the Systolic Hypertension in Europe Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677–684. Post hoc analysis of the SYST-EUR trial comparing diabetic and nondiabetic patients with isolated systolic hypertension showing that nitrendipine-based treatment decreases cardiovascular mortality only in the subgroup of diabetics.

    Article  PubMed  CAS  Google Scholar 

  25. Hansson L, Lindholm LH, Niskanen L, et al., for the Captopril Prevention Project (CAPPP) Study Group: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616. Captopril, compared with conventional therapy (diuretics and/or b-blockers), is more effective in decreasing the risk of myocardial infarction in hypertensive diabetic patients.

    Article  PubMed  CAS  Google Scholar 

  26. Burnier M, Rutschmann B, Nussberger J, et al.: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993, 22:339–347.

    PubMed  CAS  Google Scholar 

  27. Burnier M, Hagman B, Nussberger J, et al.: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995, 25:602–609.

    PubMed  CAS  Google Scholar 

  28. Schmitt F, Natov S, Martinez F, et al.: Renal effects of angiotensin II receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996, 90:205–213.

    PubMed  CAS  Google Scholar 

  29. Price DA, De Oliveira JM, Fisher NDL, Hollenberg NK: Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy man. Hypertension 1997, 30:240–246.

    PubMed  CAS  Google Scholar 

  30. Doig JK, MacFadyen RJ, Sweet CS, Reid JL: Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol 1995, 25:511–517.

    Article  PubMed  CAS  Google Scholar 

  31. Kawabata M, Takabatake T, Ohta H, et al.: Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press 1994, 5(suppl):117–121.

    CAS  Google Scholar 

  32. Erley CM, Bader B, Scheu M, et al.: Renal hemodynamics in essntial hypertensives treated with losartan. Clin Nephrol 1995, 43(suppl 1):S8-S11.

    PubMed  Google Scholar 

  33. Fauvel JP, Velon S, Berra N, et al.: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996, 28:259–263.

    Article  PubMed  CAS  Google Scholar 

  34. Nielsen S, Dollerup J, Nielsen B, et al.: Losartan reduces albuminuria in patients with essentil hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997, 12(suppl 2):19–23.

    PubMed  Google Scholar 

  35. Chan JC, Critchley JA, Tomlinson B, et al.: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997, 17:72–80.

    Article  PubMed  CAS  Google Scholar 

  36. Gansevoort RT, Sluiter W, Hemmelder MH, et al.: Antiproteinuric effect of blood pressure lowering angents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995, 10:1963–1974.

    PubMed  CAS  Google Scholar 

  37. Toto R, Shultz P, Raij L, et al.: Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998, 31:684–691.

    PubMed  CAS  Google Scholar 

  38. O’Donnell MP, Crary GS, Oda H, et al.: Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int 1997, 63(suppl):S218-S220.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit, Hospital Clïnic, 170 Villarroel, 08036, Barcelona, Spain

    Alejandro de la Sierra MD

  2. Hypertension Unit, Hospital 12 de Octubre, Carretera de Andalucïa Km 5.4, 28041, Madrid, Spain

    Luis Miguel Ruilope MD

Authors
  1. Alejandro de la Sierra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis Miguel Ruilope MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de la Sierra, A., Ruilope, L.M. Treatment of hypertension in diabetes mellitus. Current Science Inc 2, 335–342 (2000). https://doi.org/10.1007/s11906-000-0018-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-000-0018-y

Keywords

Search

Navigation